Video
Dr. Oh on a Biomarker Development Trial in mCRPC
Author(s):
William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial in metastatic castrate-resistant prostate cancer (mCRPC).
William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial in metastatic castrate-resistant prostate cancer (mCRPC). Oh was an author on the trial presented at the 2014 Genitourinary Cancers Symposium.
Satraplatin is a next-generation platinum chemotherapy drug that will not move forward in development. It is known that there is a subset of patients with advanced CRPC that respond to platinum chemotherapy, Oh says. Researchers are interested in determining this subset and are developing blood- and tissue-based biomarkers.
In prostate cancer, there are several subsets of patients that will respond to various treatments, but platinum is an important class of drug for neuroendocrine-type differentiated cancers.
